VRTX - Vertex Pharmaceuticals Incorporated

-

$undefined

N/A

(N/A)

Vertex Pharmaceuticals Incorporated NasdaqGS:VRTX Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Location: 50 Northern Avenue, Boston, MA, 02210, United States | Website: https://www.vrtx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

110.3B

Cash

6.201B

Avg Qtr Burn

-245.1M

Short % of Float

1.88%

Insider Ownership

0.16%

Institutional Own.

97.88%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Povetacicept Details
IgA Nephropathy (IgAN)

Phase 3

Data readout

JOURNAVX™ (suzetrigine) (VX-548) Details
Pain, Diabetic peripheral neuropathy

Phase 3

Data readout

Inaxaplin (VX-147) Details
APOL1-Mediated Kidney Disease (AMKD)

Phase 3

Data readout

VX-993 Details
Diabetic peripheral neuropathy (DPN)

Phase 2

Data readout

VX-993 Details
Moderate-to-severe acute pain following bunionectomy surgery

Phase 2

Data readout

JOURNAVX™ (suzetrigine) (VX-548) Details
Pain, Lumbosacral radiculopathy

Phase 2

Update

VX-407 Details
Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase 2

Initiation

Povetacicept Details
IgA nephropathy, primary membranous nephropathy (pMN)

Phase 1/2

Data readout

VX-522 Details
Cystic fibrosis

Phase 1/2

Update

Phase 1/2

Update

Phase 1

Update

VX-264 Details
Type 1 diabetes

Failed

Discontinued

VX-864 Details
Severe alpha-1 antitrypsin deficiency

Failed

Discontinued